Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
1 Aug 23
ARS
2022 FY
Annual report to shareholders
7 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
8 Mar 22
Current reports
8-K
Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
1 Apr 24
8-K
Entry into a Material Definitive Agreement
7 Mar 24
8-K
Xtant Medical Announces Record Third Quarter Revenue of $25 Million
9 Nov 23
8-K/A
Financial Statements and Exhibits
26 Oct 23
8-K
Xtant Medical Announces Acquisition of nanOss Production Operations from RTI Surgical
23 Oct 23
8-K
Changes in Registrant's Certifying Accountant
18 Aug 23
8-K
Xtant Medical Completes Acquisition of Surgalign’s Hardware and Biologics Business
10 Aug 23
8-K
Other Events
9 Aug 23
8-K
Results of Operations and Financial Condition
1 Aug 23
8-K
Acquisition to Enhance Xtant’s Growing Spinal Fusion Devices Portfolio
28 Jul 23
Registration and prospectus
S-3
Shelf registration
1 Apr 24
S-8
Registration of securities for employees
28 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
28 Jul 23
424B3
Prospectus supplement
14 Jul 23
D
$15.00 mm in equity, sold $15.00 mm, 22 investors
12 Jul 23
S-3/A
Shelf registration (amended)
11 Jul 23
S-3
Shelf registration
7 Jul 23
Proxies
DEF 14A
Definitive proxy
7 Jun 23
PRE 14A
Preliminary proxy
19 May 23
DEF 14A
Definitive proxy
20 Sep 22
DEF 14C
Information statement
9 Sep 22
PRE 14C
Preliminary information
30 Aug 22
DEF 14A
Definitive proxy
14 Jun 21
DEF 14A
Definitive proxy
10 Sep 20
DEF 14C
Information statement
10 Sep 20
PRE 14C
Preliminary information
12 Aug 20
DEF 14A
Definitive proxy
20 Sep 19
Other
EFFECT
Notice of effectiveness
9 Apr 24
EFFECT
Notice of effectiveness
14 Jul 23
CORRESP
Correspondence with SEC
11 Jul 23
UPLOAD
Letter from SEC
10 Jul 23
EFFECT
Notice of effectiveness
21 Oct 22
CORRESP
Correspondence with SEC
18 Oct 22
UPLOAD
Letter from SEC
17 Oct 22
EFFECT
Notice of effectiveness
19 May 21
UPLOAD
Letter from SEC
14 May 21
CORRESP
Correspondence with SEC
14 May 21
Ownership